Incretin responses to oral glucose and mixed meal tests and changes in fasting glucose levels during 7 years of follow-up: The Hoorn Meal Study

We conducted the first prospective observational study in which we examined the association between incretin responses to an oral glucose tolerance test (OGTT) and mixed meal test (MMT) at baseline and changes in fasting glucose levels 7 years later, in individuals who were non-diabetic at baseline. We used data from the Hoorn Meal Study; a population-based cohort study among 121 subjects, aged 61.0±6.7y. GIP and GLP-1 responses were determined at baseline and expressed as total and incremental area under the curve (tAUC and iAUC). The association between incretin response at baseline and changes in fasting glucose levels was assessed using linear regression. The average change in glucose over 7 years was 0.43 ± 0.5 mmol/l. For GIP, no significant associations were observed with changes in fasting glucose levels. In contrast, participants within the middle and highest tertile of GLP-1 iAUC responses to OGTT had significantly smaller increases (actually decreases) in fasting glucose levels; -0.28 (95% confidence interval: -0.54;-0.01) mmol/l and -0.39 (-0.67;-0.10) mmol/l, respectively, compared to those in the lowest tertile. The same trend was observed for tAUC GLP-1 following OGTT (highest tertile: -0.32 (0.61;-0.04) mmol/l as compared to the lowest tertile). No significant associations were observed for GLP-1 responses following MMT. In conclusion, within our non-diabetic population-based cohort, a low GLP-1 response to OGTT was associated with a steeper increase in fasting glucose levels during 7 years of follow-up. This suggests that a reduced GLP-1 response precedes glucose deterioration and may play a role in the etiology of type 2 diabetes mellitus.

[1]  D. Yabe,et al.  Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both? , 2017, Journal of diabetes investigation.

[2]  J. Holst,et al.  Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. , 2015, Journal of diabetes and its complications.

[3]  T. Hansen,et al.  GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study , 2015, Diabetes.

[4]  S. Kahn,et al.  Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future , 2014, The Lancet.

[5]  J. Holst,et al.  Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT. , 2013, European journal of endocrinology.

[6]  J. Holst,et al.  Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes , 2013, Diabetes Care.

[7]  D. Yabe,et al.  Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas , 2013, Journal of diabetes investigation.

[8]  J. Holst,et al.  Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies , 2013, Diabetologia.

[9]  N. Tong,et al.  Impaired Secretion of Total Glucagon-like Peptide-1 in People with Impaired Fasting Glucose Combined Impaired Glucose Tolerance , 2012, International journal of medical sciences.

[10]  C. Cobelli,et al.  Defects in GLP-1 response to an oral challenge do not play a significant role in the pathogenesis of prediabetes. , 2012, The Journal of clinical endocrinology and metabolism.

[11]  A. Lacy,et al.  Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects , 2012, Surgical Endoscopy.

[12]  J. Holst,et al.  Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? , 2010, Diabetologia.

[13]  L. Kennedy,et al.  Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus , 2009, Cleveland Clinic Journal of Medicine.

[14]  J. Holst,et al.  Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? , 2009, Diabetologia.

[15]  N. Irwin,et al.  Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications , 2009, Diabetologia.

[16]  G. Nijpels,et al.  Classical and model-based estimates of beta-cell function during a mixed meal vs. an OGTT in a population-based cohort. , 2009, Diabetes research and clinical practice.

[17]  J. Holst,et al.  The incretin system and its role in type 2 diabetes mellitus , 2009, Molecular and Cellular Endocrinology.

[18]  J. Egan,et al.  The Role of Incretins in Glucose Homeostasis and Diabetes Treatment , 2008, Pharmacological Reviews.

[19]  Andrea Mari,et al.  Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients , 2008, Diabetes.

[20]  O. Pedersen,et al.  Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action , 2008, Diabetologia.

[21]  Mark Ellrichmann,et al.  Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance , 2008, Diabetes.

[22]  T. Hansen,et al.  Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study , 2008, Diabetologia.

[23]  Sten Madsbad,et al.  Reduced Incretin Effect in Type 2 Diabetes , 2007, Diabetes.

[24]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[25]  P. Boyle,et al.  Application of Incretin Mimetics and Dipeptidyl Peptidase IV Inhibitors in Managing Type 2 Diabetes Mellitus , 2007, The Journal of the American Osteopathic Association.

[26]  J. Holst,et al.  Reduced Incretin Effect in Type 2 Diabetes - Cause or Consequence of the Diabetic State? Received for publication 23 January 2007 and accepted in revised form 3 May 2007. , 2007 .

[27]  Andrea Mari,et al.  Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance. , 2006, American journal of physiology. Endocrinology and metabolism.

[28]  M. Nauck,et al.  Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes , 2006, Diabetologia.

[29]  J. Holst,et al.  Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes , 2005, Diabetologia.

[30]  Jens J. Holst,et al.  Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes , 2004, Regulatory Peptides.

[31]  J. Holst,et al.  Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. , 2004, American journal of physiology. Endocrinology and metabolism.

[32]  A. Tura,et al.  Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. , 2004, Metabolism: clinical and experimental.

[33]  J. Holst,et al.  Incretins, insulin secretion and Type 2 diabetes mellitus , 2004, Diabetologia.

[34]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[35]  J. Holst,et al.  Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. , 2001, The Journal of clinical endocrinology and metabolism.

[36]  R. Pratley,et al.  The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus , 2001, Diabetologia.

[37]  J. Holst,et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.

[38]  J. Holst,et al.  Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. , 1997, European journal of endocrinology.

[39]  J. Holst,et al.  Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. , 1996, European journal of endocrinology.

[40]  C. McMahan,et al.  Rapid gastric emptying of an oral glucose solution in type 2 diabetic patients. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  J H Ruijs,et al.  Abdominal fat depots measured with computed tomography: effects of degree of obesity, sex, and age. , 1988, European journal of clinical nutrition.

[42]  R. Eaton,et al.  Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. , 1986, The Journal of clinical endocrinology and metabolism.

[43]  P. Giacomoni,et al.  Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity. , 1982, The Journal of clinical endocrinology and metabolism.

[44]  D. Kipnis,et al.  Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. , 1967, The Journal of clinical investigation.

[45]  M. T. Brennan,et al.  Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. , 1967, The Journal of clinical investigation.

[46]  N. Mcintyre,et al.  NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE. , 1964, Lancet.

[47]  M. Bernard.  DEFECT OF ORGANIZATION IN THE EXTERNAL EAR. , 1824 .